Jefferies Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $49.7M | Buy |
186,100
+116,100
| +166% | +$24.7M | 0.42% | 41 |
|
|
2022
Q2 | $14.3M | Buy |
70,000
+45,000
| +180% | +$9.2M | 0.12% | 132 |
|
|
2022
Q1 | $5.26M | Buy |
25,000
+19,900
| +390% | +$4.33M | 0.03% | 401 |
|
|
2021
Q4 | $1.22M | Sell |
5,100
-4,900
| -49% | -$1.26M | 0.01% | 940 |
|
|
2021
Q3 | $2.83M | Sell |
10,000
-4,000
| -29% | -$1.31M | 0.02% | 628 |
|
|
2021
Q2 | $4.85M | Sell |
14,000
-84,400
| -86% | -$25.6M | 0.03% | 468 |
|
|
2021
Q1 | $27.5M | Buy |
98,400
+75,100
| +322% | +$20.3M | 0.24% | 58 |
|
|
2020
Q4 | $5.71M | Buy |
23,300
+14,900
| +177% | +$3.84M | 0.04% | 367 |
|
|
2020
Q3 | $2.38M | Hold |
8,400
| – | – | 0.03% | 508 |
|
|
2020
Q2 | $2.25K | Sell |
8,400
-75,300
| -90% | -$22.6M | 0.03% | 511 |
|
|
2020
Q1 | $26.5M | Buy |
83,700
+55,400
| +196% | +$16.8M | 0.29% | 46 |
|
|
2019
Q4 | $8.4M | Sell |
28,300
-33,800
| -54% | -$9.38M | 0.07% | 288 |
|
|
2019
Q3 | $14.5M | Sell |
62,100
-73,700
| -54% | -$17.2M | 0.11% | 129 |
|
|
2019
Q2 | $31.8M | Sell |
135,800
-30,900
| -19% | -$7.13M | 0.23% | 58 |
|
|
2019
Q1 | $39.4M | Buy |
166,700
+145,900
| +701% | +$45.9M | 0.32% | 33 |
|
|
2018
Q4 | $6.26M | Sell |
20,800
-700
| -3% | -$223K | 0.05% | 333 |
|
|
2018
Q3 | $7.6M | Buy |
21,500
+17,300
| +412% | +$5.96M | 0.05% | 363 |
|
|
2018
Q2 | $1.22M | Sell |
4,200
-45,100
| -91% | -$12.7M | 0.01% | 1144 |
|
|
2018
Q1 | $13.5M | Buy |
49,300
+46,200
| +1,490% | +$14.3M | 0.07% | 184 |
|
|
2017
Q4 | $988K | Sell |
3,100
-8,800
| -74% | -$2.82M | ﹤0.01% | 1374 |
|
|
2017
Q3 | $3.73M | Sell |
11,900
-10,900
| -48% | -$3.23M | 0.02% | 649 |
|
|
2017
Q2 | $6.19M | Buy |
+22,800
| New | +$6.03M | 0.04% | 439 |
|
|
2017
Q1 | – | Sell |
-87,200
| Closed | -$24.7M | – | 2323 |
|
|
2016
Q4 | $24.7M | Sell |
87,200
-372,400
| -81% | -$110M | 0.14% | 117 |
|
|
2016
Q3 | $144M | Buy |
459,600
+427,500
| +1,332% | +$127M | 0.74% | 16 |
|
|
2016
Q2 | $7.76M | Buy |
32,100
+31,400
| +4,486% | +$8.28M | 0.04% | 353 |
|
|
2016
Q1 | $182K | Sell |
700
-41,100
| -98% | -$10.9M | ﹤0.01% | 1859 |
|
|
2015
Q4 | $12.8M | Sell |
41,800
-37,600
| -47% | -$10.8M | 0.07% | 212 |
|
|
2015
Q3 | $23.2M | Buy |
79,400
+78,400
| +7,840% | +$25.9M | 0.13% | 126 |
|
|
2015
Q2 | $404K | Buy |
+1,000
| New | +$401K | ﹤0.01% | 1662 |
|
|
2015
Q1 | – | Sell |
-50,700
| Closed | -$17.2M | – | 2086 |
|
|
2014
Q4 | $17.2M | Buy |
+50,700
| New | +$16.4M | 0.1% | 173 |
|
|
2013
Q4 | – | Sell |
-7,500
| Closed | -$1.81M | – | 1919 |
|
|
2013
Q3 | $1.81M | Buy |
+7,500
| New | +$1.68M | 0.02% | 646 |
|
Other funds holding BIIB
Jefferies Group's BIIB Position: Q3 2022 in Review
Jefferies Group reduced its Biogen (BIIB) stake by 100% in Q3 2022, selling an estimated $12.2M and leaving 50 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1553.
Jefferies Group first reported a position in BIIB in Q3 2013 and has held it in 36 quarters since. The position peaked at $41.4M in Q3 2016. 986 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.
- Jefferies Group held 50 shares of Biogen worth $13.3K as of Q3 2022.
- Jefferies Group sold 57,549 Biogen shares in Q3 2022, an estimated $12.2M.
- Biogen made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1553 holding.
- Jefferies Group first reported a position in Biogen in Q3 2013 and has held it in 36 quarters since.
- Jefferies Group's Biogen position peaked at $41.4M in Q3 2016.
- 986 funds tracked by Wall St. Rank held Biogen as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.